INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to Hold Rating

INmune Bio (NASDAQ:INMB) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $18.00.

INmune Bio Price Performance

Shares of NASDAQ INMB opened at $2.01 on Friday. INmune Bio has a one year low of $1.38 and a one year high of $11.64. The business’s fifty day moving average price is $1.77 and its 200-day moving average price is $2.90. The stock has a market capitalization of $53.43 million, a PE ratio of -0.95 and a beta of 0.91.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.07. As a group, equities analysts expect that INmune Bio will post -2.24 EPS for the current fiscal year.

Hedge Funds Weigh In On INmune Bio

A number of large investors have recently modified their holdings of INMB. Rhumbline Advisers increased its holdings in INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after acquiring an additional 2,409 shares during the period. MAI Capital Management boosted its holdings in INmune Bio by 6.0% in the 1st quarter. MAI Capital Management now owns 106,797 shares of the company’s stock valued at $834,000 after purchasing an additional 6,030 shares during the period. Quarry LP purchased a new position in shares of INmune Bio during the 1st quarter valued at $48,000. Charles Schwab Investment Management Inc. grew its position in shares of INmune Bio by 19.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock valued at $323,000 after purchasing an additional 6,654 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of INmune Bio by 44.8% in the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after purchasing an additional 9,236 shares during the period. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.